Health
ATPCI: Trimetazidine Fizzles for Post-PCI Angina – Medscape
The antianginal was unable to provide added benefit when added to optimal medical therapy, but one expert questions: Was the right population studied?
Adding trimetazidine to optimal medical therapy does not improve outcomes following successful percutaneous coronary intervention (PCI) for stable angina or a nonST-elevated myocardial infarction (MI), results of the ATPCI trial show.
There was no benefit for the composite primary endpoint of cardiac death, hospitalization for cardiac events, or recurrent/persistent angina requiring an addition, switch, or increased dose of antianginal therapies, or requiring coronary angiography (hazard ratio…
-
Noosa News14 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business14 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News14 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Noosa News14 hours agoQueen Street Mall to get a 3D digital billboard; Dutton dumps controversial plans to end flexible work; Measles alert for tourist hotspots